Insulin-like growth factor binding proteins (IGFBPs) play a key role in insulin and insulin growth factor signaling and are known to be expressed in several tissues. Studies on the transcriptional regulation of IGFBP genes in various cell types have suggested that IGFBPs control both systemic hormones and regulators. Also, the complex regulatory mechanisms involved in both transcription and translation of IGFBPs provide evidence for molecular mechanisms by which growth factor-and hormone-mediated gene expression are regulated. In particular, IGFBP-1 is known to be an important regulator of IGF activity and mainly regulates metabolism in mammals. In this review, we focus on recent progress in elucidating the transcriptional regulation of IGFBP-1 among IGFBP isoforms.
INTRODUCTION
The insulin-like growth factor binding proteins (IGFBPs) are a superfamily comprised of six proteins (IGFBP-1 to 6) that bind to IGFs with high affinity. The existence of IGFBPs was discovered in the 1960s, and most studies were performed after the cloning of six IGFBPs in the early 1990s [1] . IGFBPs are commonly composed of a long amino acid sequence. IGFBPs are not only involved in IGF action, but also appear to regulate IGF-independent functions including inhibition or activation of cell growth and induction of apoptosis [2] . IGFBPs interact with the acid-labile subunits and glycoproteins as well as insulin-like growth factors (IGFs) in serum [3] . Recently, another group of proteins which have a low affinity with IGFs was discovered and named IGFBPrelated proteins (IGFBP-rPs) even though their structures are similar to the classical IGFBPs [4] .
IGFBPs are regulated by proteases released from several tissues, and their IGF binding affinity is negatively affected by proteolytic cleavage as well as phosphorylation of IGFBPs [4] . The exact physiological importance of these mechanisms, however, is still unclear. The characteristics of the six IGFBPs are summarized in Table 1 . When IGFs are secreted and circulate freely, they are unstable and easily degraded. To achieve functional stability, they need to bind IGFBPs for effective circulation in the blood. Lately, IGFBPs have demonstrated multiple functions as potential players in pathophysiological diseases including cancer, metabolic disease and neuronal disease [5] .
In this review, we outline the relationship between IGFBP-1 and metabolic disease. Furthermore, we overview the transcriptional regulation of IGFBP-1 and discuss current evidence that supports the effects of IGFBP-1 gene expression on metabolic signaling. Understanding the transcriptional regulation of IGFBPs will expand our knowledge and research of the pathogenesis of metabolic disease and identify potential therapeutic targets against metabolic diseases. 
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REGULATORY MECHANISM AND PHYSIOLOGICAL FUNCTION OF IGFBP-1
IGFBP-1, among the IGFBP family, is produced dominantly in the liver and kidney [6] . The N-and C-terminals of IGBFP-1 are highly conserved among the IGFBP isoforms and contribute to binding with IGF [7] . IGFBP-1 has central linker domains affected by post-translational modifications including proteolysis and phosphorylation [8] . IGFBP-1 can affect IGF-1 activity on cellular responses and independently activates IGF-1 action on cell signaling [9, 10] . IGFBP-1 not only is an important determinant of IGF activity, but also enhances glucose uptake in peripheral tissues and reduces glucose output in liver. Moreover, it plays a role in lipid metabolism [11] .
IGFBP-1 has been identified as a phosphoprotein and contains three phosphorylation sites [12] . IGFBP-1 phosphorylation induces the development of retinopathy centers.
In addition, activity of IGFBP-1 is regulated by both phosphorylation and dephosphorylation. The phosphorylated form of IGFBP-1 shows an enhanced affinity to IGF-1 and II, thereby reducing the utility of IGFs. Regulation of IGF activity by IGFBPs, however, is very complicated in both stimulatory and inhibitory mechanisms [13] . Because the af- The location of the IGFBP family is described in Fig. 1 . The evolutionary relationship between the different IGFBP isoforms is well explained by genome duplication in vertebrates [16] . Along with the historical aspect for the analysis of IGFBP evolution, there are also functional implications when considering genome duplications. IGFBPs form part of [20] . cAMP is a commonly used decidualization stimulus, which is involved in the process of differentiating fibroblastoid stromal cells of the estrogen-primed endometrium by progesterone [21] . Decidualization of stromal cells is induced by biochemical stimuli in vitro and in vivo. cAMP is known to be an activator of IGFBP-1 and increases IGFBP-1 gene expression in ESCs. Two cAMP response elements (CREs) have been found on the IGFBP-1 promoter (Fig. 2) . In addition to cAMP, the effect of metformin on decidualization was revealed in ESCs [22] .
Metformin has been identified as an anti-diabetic drug.
However, Tamura A previous study has suggested that insulin inhibits hepatic IGFBP-1 gene expression, and that IGFBP-1 levels rapidly declined after feeding [27] . These data indicate that IGFBP-1 level in serum is related to plasma insulin level.
Because IGFBP-1 mRNA expression increases during fasting, glucagon seems to stimulate plasma insulin level [28] .
These results suggest that IGFBP-1 gene transcription might play a key role in a complicated metabolic regulation. In addition to the effect of glucocorticoid as a transcription factor of IGFBP transcription through GRE, IGFBP-1 gene expression is regulated by CAAT/enhancer-binding proteins (C/EBPs) [30] (Fig. 2) . In the liver, the effects of insulin [34, 35] . IGFBP-1 level is decreased in fasting serum of early NIDDM patients with insulin resistance [36, 37] .
Overexpression of IGFBP-1 has been shown to improve impaired glucose tolerance. On the other hand, serum IGF-1 is reduced while IGFBP-1 level is increased in type 1 diabetic patients [38] .
IGFBP-1 secretion is regulated by a variety of pathological and physiological signals [39] . Serum level of IGFBP-1 is associated with metabolic nutritional factors and increases IGF-1 concentration, resulting in reciprocal regulation of plasma insulin level. Glucagon acts as an activator of serum IGFBP-1 independently of insulin level [28] . This implies a complicated metabolic regulation of IGFBP-1. Various evidences suggest that malfunction of the IGFBP-1 system is involved in the long-term complications of diabetes mellitus [40] . Low levels of IGFBP in serum identify insulin resistance as a marker of insulin sensitivity. Therefore, IGFBP-1 level can correlate well with common indicators of insulin resistance in obese children and adults [41] .
Inflammation plays a pivotal role in atherosclerosis development [42] . Recent studies demonstrated that secretion of IGFBP-1 is activated by proinflammatory cytokines like IL-1β and TNFα in HepG2 liver hepatocarcinoma cell lines [43, 44] . In addition, IL-6 upregulates mRNA expression and secretion of IGFBP-1 in a dose-dependent manner in hepatocytes which are co-cultured with liver macrophages [45] . Therefore, the concentration of IGFBP-1 regulated by cytokines may be involved in the initiation and progression of cardiovascular disease.
CONCLUSION
This article aimed to discuss the regulation of the IGFBP-1 in metabolic diseases like diabetes and cardiovascular disease. 
